scholarly journals Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?

2016 ◽  
Vol 9 (5) ◽  
pp. 426-436 ◽  
Author(s):  
Sara Ariotti ◽  
Marianna Adamo ◽  
Francesco Costa ◽  
Athanasios Patialiakas ◽  
Carlo Briguori ◽  
...  
2020 ◽  
Author(s):  
Camila Correa-Sadouet ◽  
A Matías Rodríguez-Granillo ◽  
Camila Gallardo ◽  
Juan Mieres ◽  
Lucía Fontana ◽  
...  

The use of colchicine is associated with a significant reduction of cardiac adverse events in patients with coronary artery disease. Past small randomized trials with oral immunosuppressive or anti-inflammatory therapies have demonstrated a reduction of adverse clinical events after bare metal stent implantation. The potential role of adjunctive colchicine after bare-metal stent implantation, compared with drug-eluting stent alone, is unknown. The primary end point of the study will be to compare cost–effectiveness at 1 year of follow-up of coronary intervention with bare-metal stent implantation plus 1 mg of colchicine during 3 months versus percutaneous coronary intervention with drug-eluting stent implantation alone. ClinicalTrials.gov  identifier: NCT04382443


2018 ◽  
Vol 38 (2) ◽  
pp. 62
Author(s):  
Tien-Ping Tsao ◽  
Wen-Cheng Liu ◽  
Min-Chien Tsai ◽  
Cheng-Chung Cheng ◽  
Sy-Jou Chen ◽  
...  

2011 ◽  
Vol 45 (10) ◽  
pp. 1307-1307 ◽  
Author(s):  
Sarah R Peppard ◽  
Bethanne M Held-Godgluck ◽  
Richard Beddingfield

Objective: To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. Case Summary: A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed Stephens-Johnson syndrome 6 years earlier following Clopidogrel administration, characterized by erythematous plaques and subsequent desquamation of the hands and feet; Clopidogrel was discontinued and he was subsequently treated with ticlopidine in addition to aspirin. The third-generation thienopyridine prasugrel was initiated as a therapeutic alternative to Clopidogrel after placement of a bare metal stent; a 60-mg dose was administered after extubation, followed by 10 mg/day. No signs of allergic reaction were observed in the days, weeks, and months following administration. Discussion: Thienopyridines, specifically Clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents. One study demonstrated that 27% of patients who developed an allergic or hematologic reaction to Clopidogrel developed a similar reaction to ticlopidine. Other therapeutic options for patients with Clopidogrel hypersensitivity who are undergoing a percutaneous coronary intervention with stent placement include Clopidogrel desensitization, warfarin plus aspirin, cilostazol, ticagrelor, and ticlopidine. However, these options are limited by efficacy and/or toxicity. With its approval in 2009, prasugrel has become a potential treatment option. Conclusions: Prasugrel may be considered a therapeutic alternative in some patients allergic or intolerant to Clopidogrel, but additional data are warranted to make a strong conclusion.


Sign in / Sign up

Export Citation Format

Share Document